Unknown

Dataset Information

0

CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.


ABSTRACT: Cancer immunotherapy has gained attention as the supreme therapeutic modality for the treatment of various malignancies. Adoptive T-cell therapy (ACT) is one of the most distinctive modalities of this therapeutic approach, which seeks to harness the potential of combating cancer cells by using autologous or allogenic tumor-specific T-cells. However, a plethora of circumstances must be optimized to produce functional, durable, and efficient T-cells. Recently, the potential of ACT has been further realized by the introduction of novel gene-editing platforms such as the CRISPR/Cas9 system; this technique has been utilized to create T-cells furnished with recombinant T-cell receptor (TCR) or chimeric antigen receptor (CAR) that have precise tumor antigen recognition, minimal side effects and treatment-related toxicities, robust proliferation and cytotoxicity, and nominal exhaustion. Here, we aim to review and categorize the recent breakthroughs of genetically modified TCR/CAR T-cells through CRISPR/Cas9 technology and address the pearls and pitfalls of each method. In addition, we investigate the latest ongoing clinical trials that are applying CRISPR-associated TCR/CAR T-cells for the treatment of cancers.

SUBMITTER: Ghaffari S 

PROVIDER: S-EPMC8390258 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC1131930 | biostudies-literature
| S-EPMC7474265 | biostudies-literature
| S-EPMC7791012 | biostudies-literature
| S-EPMC8172808 | biostudies-literature
| S-EPMC5555975 | biostudies-other
| S-EPMC7005203 | biostudies-literature
| S-EPMC10658519 | biostudies-literature
| S-EPMC6315587 | biostudies-literature
| S-EPMC7463827 | biostudies-literature
| S-EPMC4239020 | biostudies-literature